International Research Journal of Oncology 2021-06-12T10:51:15+00:00 International Research Journal of Oncology Open Journal Systems <p style="text-align: justify;"><strong>International Research Journal of Oncology</strong>&nbsp;aims to publish case reports related to all aspects of oncology.&nbsp;The journal also encourages the submission of useful reports of negative results. This is a quality controlled,&nbsp;OPEN&nbsp;peer-reviewed, open access INTERNATIONAL journal.&nbsp;</p> Recurrent Dermatofibrosarcoma Protruberance over Shoulder: An Unresolved Problem 2021-06-05T12:54:30+00:00 Sachin S. Kadam Tejaswini Kadam <p><strong>Introduction:</strong> We are reporting a case of recurrent Dermatofibrosarcoma protuberans (DFSP) over right shoulder in a 36 year young lady who underwent re-excision with secondary healing. DFSP is common in both, men and women with a slight male predominance. They are characterized by a unique translocation of chromosome i.e. t(17;22) (q22;q13). Majority of DFSPs are low grade (85-90 %) while the rest contain a high-grade sarcomatous component (DFSP-FS) and are considered to be intermediate-grade sarcomas. Trunk and proximal extremities are the most common location, usually on the chest and shoulders. Persistently recurring tumors have an increased risk for transformation into a more malignant form (DFSP-FS). Metastases to regional lymph nodes are extremely rare and distant hematogenous metastases are even rarer. Adequate lateral and deeper margin resection is necessary for excision of resectable primary DFSP and team approach is must for tackling recurrent and metastatic DFSP.</p> 2021-06-05T00:00:00+00:00 ##submission.copyrightStatement## Lymphatic Injury and Peripheral Lymphedema as Complications of Central Venous Catheter: A Case Report and a Literature Review 2021-05-18T09:00:46+00:00 Luis Lopez Montoya D. Yucari Lopez Joceline Sandoval Angel Lopez Montoya Roberto Garcia Valadez Claudia Paz Luna Itzel Alcaraz Arevalo <p><strong>Introduction: </strong>Secondary lymphedema is defined as a chronic-progressive disease which causes a rich protein edema of the limbs, this may be caused due to the damage or obstruction of lymphatic structures; secondary peripheral lymphedema may be considered a complication of central venous catheter procedures.</p> <p><strong>Objective: </strong>To describe a clinical case of upper extremity lymphedema as venous port catheter related complication and present a review of literature of lymphatic complications of central venous catheter.</p> <p><strong>Case Presentation: </strong>A 57-year-old woman received previous medical attention between 2019-2020 due to Hodgkin lymphoma; the patient was diagnosed by left cervical lymph node biopsy and received 12 chemotherapy cycles through right subclavian catheter. The patient arrived to our facilities in March 2021 to assess her case due to increased right arm volume related to progressive edema that did not improve with rest or elevation and began to limit movements and basic activities; the situation began after a previous right catheter infection and a change of it in January 2020 with no evidence of venous thrombosis and identified a worsening tendency with time since last chemotherapy in May 2020. After clinical history, physical examination and ICG NIR lymphography study, lymphedema was confirmed as a result of subclavian catheter related complication. We decided to present the case along a literature review on the topic.</p> <p><strong>Conclusion: </strong>Lymphatic injury and peripheral lymphedema related to Central Venous Catheter procedures and its complications is a clinical reality that might be underrecognized and underdiagnosed by scientific literature and clinicians; this condition should be properly studied and deeply considered with the adequate assessment strategies in patients undergoing CVC procedures in the mid and long term to avoid its undertreatment.</p> 2021-05-18T00:00:00+00:00 ##submission.copyrightStatement## A Prospective Observational Study of the Efficacy of Neoadjuvant Chemotherapy in Newly Diagnosed Inoperable Patients of Epithelial Ovarian Cancer 2021-06-12T10:51:15+00:00 S. Janarthan Babu Rakesh Sharma A. V. S. Suresh S. S Nirni P. S. Dattatreya A. Vindhya Vasini <p><strong>Introduction: </strong>Ovarian cancer is the leading cause of death from gynecological cancers in developed countries. More than 70% of patients have Stage III – IV disease at diagnosis. The standard of care for advanced ovarian cancer is primary debulking surgery (PDS) followed by adjuvant (ADJ) chemotherapy. There are very few prospective randomized Indian studies that have evaluated the effectiveness of neoadjuvant chemotherapy (NACT) in advanced ovarian cancer. This study attempted to evaluate the efficacy of NACT in advanced epithelial ovarian cancer patients who were unfit for upfront surgery.</p> <p><strong>Methods:</strong> This was a prospective observational study involving newly diagnosed patients with inoperable epithelial ovarian cancer, conducted over a period of 18 months from October 2016 to March 2018 at the department of Medical Oncology at a tertiary care oncology center, situated in Hyderabad, India. Detailed clinical history, laboratory reports, imaging and histopathological reports were obtained and maintained in a standard proforma.</p> <p><strong>Results: </strong>The median age at presentation was 51 years with a range of 37 to 70 years. 82.8% of the cases belonged to international federation of obstetrics and gynecology (FIGO) stage III. The objective response rate to NACT was 85.93% and the optimal cytoreduction rate was 85.96%. Post operative grade 3 or 4 adverse events were observed in 19.3% of the patients.</p> <p><strong>Conclusion: </strong>Neoadjuvant chemotherapy is an alternative approach to primary debulking surgery for advanced ovarian cancers. Among inoperable advanced epithelial ovarian cancer patients, neoadjuvant chemotherapy is associated with good objective response rates. Patients undergoing interval debulking surgery following neoadjuvant chemotherapy had less peri-operative morbidity and mortality.</p> 2021-06-12T00:00:00+00:00 ##submission.copyrightStatement##